世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

放射性医薬品セラノスティックス市場(ラジオアイソトープ:テクネチウム-99、ガリウム-68、ヨウ素-131、ラジウム-223、フッ素-18、イットリウム-90、ルテチウム-177、銅-67&64、サマリウム-153、その他) - 世界の産業分析、サイズ、シェア、成長、動向、予測、2023-2031年


Radiopharmaceutical Theranostics Market (Radioisotope: Technetium-99, Gallium-68, Iodine-131, Radium-223, Fluorine-18, Yttrium-90, Lutetium-177, Copper-67 & 64, Samarium-153, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

放射性医薬品セラノスティクス市場 - レポートの範囲 TMRの調査レポート「放射性医薬品セラノスティックスの世界市場」は、2023年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Transparency Market Research
トランスペアレンシーマーケットリサーチ
2023年3月20日 US$5,795
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
180 英語

 

サマリー

放射性医薬品セラノスティクス市場 - レポートの範囲
TMRの調査レポート「放射性医薬品セラノスティックスの世界市場」は、2023年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成長動向と機会も調査しています。本レポートでは、2023年を基準年、2031年を予測年として、2017年から2031年までの期間における世界の放射性医薬品セラノスティクス市場の収益を提供します。また、2023年から2031年までの放射性医薬品セラノスティクスの世界市場の年間複合成長率(CAGR %)を掲載しています。

本レポートは、広範な調査を経て作成されました。一次調査では、主要なオピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施し、調査作業の大部分を行いました。二次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、放射性医薬品セラノスティクス市場を把握しました。

また、インターネット上の情報源や政府機関、ウェブサイト、業界団体の統計データも二次調査の対象としています。アナリストは、トップダウンアプローチとボトムアップアプローチを組み合わせて、世界の放射性医薬品セラノスティクス市場の様々な属性を調査しました。

本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、放射性医薬品セラノスティクスの世界市場における競争力学の変化にも光を当てています。これらは、既存の市場関係者だけでなく、世界の放射性医薬品セラノスティックス市場への参入に関心のある企業にとっても、貴重なツールとなります。

本レポートは、世界の放射性医薬品セラノスティクス市場の競争環境について掘り下げています。世界の放射性医薬品セラノスティックス市場で活動する主要企業が特定され、それぞれの企業が様々な属性でプロファイリングされています。会社概要、財務状況、最近の開発状況、SWOTは、本レポートで紹介されている世界の放射性医薬品セラノスティクス市場のプレイヤーの属性です。

放射性医薬品セラノスティックスの世界市場レポートで回答した主要な質問
- 予測期間中に全地域で放射性医薬品セラノスティックスが生み出した売上/収益はどの程度か?
- 放射性医薬品セラノスティックスの世界市場における機会は何か?
- 市場の主な推進要因、阻害要因、機会、脅威は何か?
- 予測期間中に最も速いCAGRで拡大するのはどの地域市場か?
- 2031年に世界で最も高い収益を上げると予測されるセグメントは?
- 予測期間中に最も高いCAGRで拡大すると予測されるセグメントはどこか?
- 世界市場で事業展開している各社の市場ポジションは?

放射性医薬品セラノスティックス市場 - 研究目的と研究アプローチ
放射性医薬品セラノスティックスの世界市場に関する包括的なレポートは、概要から始まり、研究の範囲と目的について説明しています。本調査の目的、市場で活動する主要ベンダーや流通業者、製品の承認に関する規制シナリオについて詳しく解説しています。

読みやすさを考慮し、本レポートは章立てでまとめられ、各セクションはより小さなものに分割されています。本レポートは、グラフと表が適切に配置された包括的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化し、読者に視覚的に訴えかけています。また、過去と予測期間終了時の主要セグメントの市場シェアを比較することも可能です。

本レポートでは、世界の放射性医薬品セラノスティックス市場を製品、エンドユーザー、地域の観点から分析しています。各基準の主要セグメントを詳細に調査し、2031年末時点の各セグメントごとの市場シェアを掲載しています。このような貴重な洞察により、市場関係者は、世界の放射性医薬品セラノスティクス市場への投資について、情報に基づいたビジネス上の意思決定を行うことができます。

ページTOPに戻る


目次

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Radiopharmaceutical Theranostics Market
4. Market Overview
    4.1. Introduction
        4.1.1. Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, 2017-2031
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Regulatory Scenario
    5.2. Key Distribution Strategies
    5.3. Pricing Analysis
    5.4. Patents on Radiotracers
    5.5. Technological Advancements in Radiopharmaceutical Theranostics
    5.6. Radiotracer Type - Overview
    5.7. COVID-19 Pandemic Impact on Industry
6. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Radioisotope
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Radioisotope, 2017-2031
        6.3.1. Technetium-99
        6.3.2. Gallium-68
        6.3.3. Iodine-131
        6.3.4. Radium-223
        6.3.5. Fluorine-18
        6.3.6. Yttrium-90
        6.3.7. Lutetium-177
        6.3.8. Copper-67 & 64
        6.3.9. Samarium-153
        6.3.10. Others
    6.4. Market Attractiveness Analysis, by Radioisotope
7. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Application
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Application, 2017-2031
        7.3.1. Oncology
        7.3.2. Cardiology
        7.3.3. Others
    7.4. Market Attractiveness Analysis, by Application
8. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Source
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Source, 2017-2031
        8.3.1. Nuclear Reactors
        8.3.2. Cyclotrons
    8.4. Market Attractiveness Analysis, by Source
9. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Approach
    9.1. Introduction & Definition
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by Approach, 2017-2031
        9.3.1. Targeted Therapeutic (Rx)
        9.3.2. Companion Diagnostic (DX)
    9.4. Market Attractiveness Analysis, by Approach
10. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Radiotracer Type
    10.1. Introduction & Definition
    10.2. Key Findings/Developments
    10.3. Market Value Forecast, by Radiotracer Type, 2017-2031
        10.3.1. Peptidic
        10.3.2. Non-peptidic
    10.4. Market Attractiveness Analysis, by Radiotracer Type
11. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by End-user
    11.1. Introduction & Definition
    11.2. Key Findings/Developments
    11.3. Market Value Forecast, by End-user, 2017-2031
        11.3.1. Hospitals
        11.3.2. Academic & Research Institutes
        11.3.3. Others
    11.4. Market Attractiveness Analysis, by End-user
12. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Region
    12.1. Key Findings
    12.2. Market Value Forecast, by Region, 2017-2031
        12.2.1. U.S.
        12.2.2. Europe
        12.2.3. Rest of the World
    12.3. Market Attractiveness Analysis, by Region
13. U.S. Radiopharmaceutical Theranostics Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Radioisotope, 2017-2031
        13.2.1. Technetium-99
        13.2.2. Gallium-68
        13.2.3. Iodine-131
        13.2.4. Radium-223
        13.2.5. Fluorine-18
        13.2.6. Yttrium-90
        13.2.7. Lutetium-177
        13.2.8. Copper-67 & 64
        13.2.9. Samarium-153
        13.2.10. Others
    13.3. Market Value Forecast, by Application, 2017-2031
        13.3.1. Oncology
        13.3.2. Cardiology
        13.3.3. Others
    13.4. Market Value Forecast, by Source, 2017-2031
        13.4.1. Nuclear Reactors
        13.4.2. Cyclotrons
    13.5. Market Value Forecast, by Approach, 2017-2031
        13.5.1. Targeted Therapeutic (Rx)
        13.5.2. Companion Diagnostic (DX)
    13.6. Market Value Forecast, by Radiotracer Type, 2017-2031
        13.6.1. Peptidic
        13.6.2. Non-peptidic
    13.7. Market Value Forecast, by End-user, 2017-2031
        13.7.1. Hospitals
        13.7.2. Academic & Research Institutes
        13.7.3. Others
    13.8. Market Attractiveness Analysis
        13.8.1. By Radioisotope
        13.8.2. By Application
        13.8.3. By Source
        13.8.4. By Approach
        13.8.5. By Radiotracer Type
        13.8.6. By End-user
14. Europe Radiopharmaceutical Theranostics Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Radioisotope, 2017-2031
        14.2.1. Technetium-99
        14.2.2. Gallium-68
        14.2.3. Iodine-131
        14.2.4. Radium-223
        14.2.5. Fluorine-18
        14.2.6. Yttrium-90
        14.2.7. Lutetium-177
        14.2.8. Copper-67 & 64
        14.2.9. Samarium-153
        14.2.10. Others
    14.3. Market Value Forecast, by Application, 2017-2031
        14.3.1. Oncology
        14.3.2. Cardiology
        14.3.3. Others
    14.4. Market Value Forecast, by Source, 2017-2031
        14.4.1. Nuclear Reactors
        14.4.2. Cyclotrons
    14.5. Market Value Forecast, by Approach, 2017-2031
        14.5.1. Targeted Therapeutic (Rx)
        14.5.2. Companion Diagnostic (DX)
    14.6. Market Value Forecast, by Radiotracer Type, 2017-2031
        14.6.1. Peptidic
        14.6.2. Non-peptidic
    14.7. Market Value Forecast, by End-user, 2017-2031
        14.7.1. Hospitals
        14.7.2. Academic & Research Institutes
        14.7.3. Others
    14.8. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.8.1. Germany
        14.8.2. U.K.
        14.8.3. France
        14.8.4. Italy
        14.8.5. Spain
        14.8.6. Rest of Europe
    14.9. Market Attractiveness Analysis
        14.9.1. By Radioisotope
        14.9.2. By Application
        14.9.3. By Source
        14.9.4. By Approach
        14.9.5. By Radiotracer Type
        14.9.6. By End-user
        14.9.7. By Country/Sub-region
15. Rest of the World Radiopharmaceutical Theranostics Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Radioisotope, 2017-2031
        15.2.1. Technetium-99
        15.2.2. Gallium-68
        15.2.3. Iodine-131
        15.2.4. Radium-223
        15.2.5. Fluorine-18
        15.2.6. Yttrium-90
        15.2.7. Lutetium-177
        15.2.8. Copper-67 & 64
        15.2.9. Samarium-153
        15.2.10. Others
    15.3. Market Value Forecast, by Application, 2017-2031
        15.3.1. Oncology
        15.3.2. Cardiology
        15.3.3. Others
    15.4. Market Value Forecast, by Source, 2017-2031
        15.4.1. Nuclear Reactors
        15.4.2. Cyclotrons
    15.5. Market Value Forecast, by Approach, 2017-2031
        15.5.1. Targeted Therapeutic (Rx)
        15.5.2. Companion Diagnostic (DX)
    15.6. Market Value Forecast, by Radiotracer Type, 2017-2031
        15.6.1. Peptidic
        15.6.2. Non-peptidic
    15.7. Market Value Forecast, by End-user, 2017-2031
        15.7.1. Hospitals
        15.7.2. Academic & Research Institutes
        15.7.3. Others
    15.8. Market Attractiveness Analysis
        15.8.1. By Radioisotope
        15.8.2. By Application
        15.8.3. By Source
        15.8.4. By Approach
        15.8.5. By Radiotracer Type
        15.8.6. By End-user
16. Competition Landscape
    16.1. Market Player Competition Matrix (by tier and size of companies)
    16.2. Market Share Analysis, by Company (2022)
    16.3. Company Profiles
        16.3.1. Advanced Accelerator Applications (Novartis AG)
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Product Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. Aurobindo Pharma
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Product Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. Bayer AG
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Product Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. Blue Earth Diagnostics (Bracco)
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Product Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. Cardinal Health
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Product Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. Clarity Pharmaceuticals
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Product Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. GE Healthcare
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Product Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. Jubliant Radiopharma
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Product Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. Lantheus Medical Imaging
            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.9.2. Product Portfolio
            16.3.9.3. Financial Overview
            16.3.9.4. SWOT Analysis
            16.3.9.5. Strategic Overview
        16.3.10. Navidea Biopharmaceuticals, Inc.
            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.10.2. Product Portfolio
            16.3.10.3. Financial Overview
            16.3.10.4. SWOT Analysis
            16.3.10.5. Strategic Overview
        16.3.11. SOFIE
            16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.11.2. Product Portfolio
            16.3.11.3. Financial Overview
            16.3.11.4. SWOT Analysis
            16.3.11.5. Strategic Overview
        16.3.12. Telix Pharmaceuticals
            16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.12.2. Product Portfolio
            16.3.12.3. Financial Overview
            16.3.12.4. SWOT Analysis
            16.3.12.5. Strategic Overview

ページTOPに戻る



図表リスト

List of Tables

Table 01: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031

Table 02: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 03: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017–2031

Table 04: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017–2031

Table 05: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017–2031

Table 06: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 07: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Region, 2017–2031

Table 08: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031

Table 09: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 10: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017–2031

Table 11: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017–2031

Table 12: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017–2031

Table 13: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 14: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 15: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031

Table 16: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 17: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017–2031

Table 18: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017–2031

Table 19: EU Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017–2031

Table 20: EU Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 21: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031

Table 22: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 23: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017–2031

Table 24: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017–2031

Table 25: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017–2031

Table 26: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

 

ページTOPに戻る


 

Summary

Radiopharmaceutical Theranostics Market – Scope of Report
TMR’s report on the global radiopharmaceutical theranostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global radiopharmaceutical theranostics market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global radiopharmaceutical theranostics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the radiopharmaceutical theranostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global radiopharmaceutical theranostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global radiopharmaceutical theranostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global radiopharmaceutical theranostics market.

The report delves into the competitive landscape of the global radiopharmaceutical theranostics market. Key players operating in the global radiopharmaceutical theranostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global radiopharmaceutical theranostics market profiled in this report.

Key Questions Answered in Global Radiopharmaceutical Theranostics Market Report
• What is the sales/revenue generated by radiopharmaceutical theranostics across all regions during the forecast period?
• What are the opportunities in the global radiopharmaceutical theranostics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Radiopharmaceutical Theranostics Market – Research Objectives and Research Approach
The comprehensive report on the global radiopharmaceutical theranostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global radiopharmaceutical theranostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global radiopharmaceutical theranostics market.



ページTOPに戻る


Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Radiopharmaceutical Theranostics Market
4. Market Overview
    4.1. Introduction
        4.1.1. Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, 2017-2031
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Regulatory Scenario
    5.2. Key Distribution Strategies
    5.3. Pricing Analysis
    5.4. Patents on Radiotracers
    5.5. Technological Advancements in Radiopharmaceutical Theranostics
    5.6. Radiotracer Type - Overview
    5.7. COVID-19 Pandemic Impact on Industry
6. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Radioisotope
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Radioisotope, 2017-2031
        6.3.1. Technetium-99
        6.3.2. Gallium-68
        6.3.3. Iodine-131
        6.3.4. Radium-223
        6.3.5. Fluorine-18
        6.3.6. Yttrium-90
        6.3.7. Lutetium-177
        6.3.8. Copper-67 & 64
        6.3.9. Samarium-153
        6.3.10. Others
    6.4. Market Attractiveness Analysis, by Radioisotope
7. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Application
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Application, 2017-2031
        7.3.1. Oncology
        7.3.2. Cardiology
        7.3.3. Others
    7.4. Market Attractiveness Analysis, by Application
8. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Source
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Source, 2017-2031
        8.3.1. Nuclear Reactors
        8.3.2. Cyclotrons
    8.4. Market Attractiveness Analysis, by Source
9. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Approach
    9.1. Introduction & Definition
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by Approach, 2017-2031
        9.3.1. Targeted Therapeutic (Rx)
        9.3.2. Companion Diagnostic (DX)
    9.4. Market Attractiveness Analysis, by Approach
10. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Radiotracer Type
    10.1. Introduction & Definition
    10.2. Key Findings/Developments
    10.3. Market Value Forecast, by Radiotracer Type, 2017-2031
        10.3.1. Peptidic
        10.3.2. Non-peptidic
    10.4. Market Attractiveness Analysis, by Radiotracer Type
11. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by End-user
    11.1. Introduction & Definition
    11.2. Key Findings/Developments
    11.3. Market Value Forecast, by End-user, 2017-2031
        11.3.1. Hospitals
        11.3.2. Academic & Research Institutes
        11.3.3. Others
    11.4. Market Attractiveness Analysis, by End-user
12. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Region
    12.1. Key Findings
    12.2. Market Value Forecast, by Region, 2017-2031
        12.2.1. U.S.
        12.2.2. Europe
        12.2.3. Rest of the World
    12.3. Market Attractiveness Analysis, by Region
13. U.S. Radiopharmaceutical Theranostics Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Radioisotope, 2017-2031
        13.2.1. Technetium-99
        13.2.2. Gallium-68
        13.2.3. Iodine-131
        13.2.4. Radium-223
        13.2.5. Fluorine-18
        13.2.6. Yttrium-90
        13.2.7. Lutetium-177
        13.2.8. Copper-67 & 64
        13.2.9. Samarium-153
        13.2.10. Others
    13.3. Market Value Forecast, by Application, 2017-2031
        13.3.1. Oncology
        13.3.2. Cardiology
        13.3.3. Others
    13.4. Market Value Forecast, by Source, 2017-2031
        13.4.1. Nuclear Reactors
        13.4.2. Cyclotrons
    13.5. Market Value Forecast, by Approach, 2017-2031
        13.5.1. Targeted Therapeutic (Rx)
        13.5.2. Companion Diagnostic (DX)
    13.6. Market Value Forecast, by Radiotracer Type, 2017-2031
        13.6.1. Peptidic
        13.6.2. Non-peptidic
    13.7. Market Value Forecast, by End-user, 2017-2031
        13.7.1. Hospitals
        13.7.2. Academic & Research Institutes
        13.7.3. Others
    13.8. Market Attractiveness Analysis
        13.8.1. By Radioisotope
        13.8.2. By Application
        13.8.3. By Source
        13.8.4. By Approach
        13.8.5. By Radiotracer Type
        13.8.6. By End-user
14. Europe Radiopharmaceutical Theranostics Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Radioisotope, 2017-2031
        14.2.1. Technetium-99
        14.2.2. Gallium-68
        14.2.3. Iodine-131
        14.2.4. Radium-223
        14.2.5. Fluorine-18
        14.2.6. Yttrium-90
        14.2.7. Lutetium-177
        14.2.8. Copper-67 & 64
        14.2.9. Samarium-153
        14.2.10. Others
    14.3. Market Value Forecast, by Application, 2017-2031
        14.3.1. Oncology
        14.3.2. Cardiology
        14.3.3. Others
    14.4. Market Value Forecast, by Source, 2017-2031
        14.4.1. Nuclear Reactors
        14.4.2. Cyclotrons
    14.5. Market Value Forecast, by Approach, 2017-2031
        14.5.1. Targeted Therapeutic (Rx)
        14.5.2. Companion Diagnostic (DX)
    14.6. Market Value Forecast, by Radiotracer Type, 2017-2031
        14.6.1. Peptidic
        14.6.2. Non-peptidic
    14.7. Market Value Forecast, by End-user, 2017-2031
        14.7.1. Hospitals
        14.7.2. Academic & Research Institutes
        14.7.3. Others
    14.8. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.8.1. Germany
        14.8.2. U.K.
        14.8.3. France
        14.8.4. Italy
        14.8.5. Spain
        14.8.6. Rest of Europe
    14.9. Market Attractiveness Analysis
        14.9.1. By Radioisotope
        14.9.2. By Application
        14.9.3. By Source
        14.9.4. By Approach
        14.9.5. By Radiotracer Type
        14.9.6. By End-user
        14.9.7. By Country/Sub-region
15. Rest of the World Radiopharmaceutical Theranostics Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Radioisotope, 2017-2031
        15.2.1. Technetium-99
        15.2.2. Gallium-68
        15.2.3. Iodine-131
        15.2.4. Radium-223
        15.2.5. Fluorine-18
        15.2.6. Yttrium-90
        15.2.7. Lutetium-177
        15.2.8. Copper-67 & 64
        15.2.9. Samarium-153
        15.2.10. Others
    15.3. Market Value Forecast, by Application, 2017-2031
        15.3.1. Oncology
        15.3.2. Cardiology
        15.3.3. Others
    15.4. Market Value Forecast, by Source, 2017-2031
        15.4.1. Nuclear Reactors
        15.4.2. Cyclotrons
    15.5. Market Value Forecast, by Approach, 2017-2031
        15.5.1. Targeted Therapeutic (Rx)
        15.5.2. Companion Diagnostic (DX)
    15.6. Market Value Forecast, by Radiotracer Type, 2017-2031
        15.6.1. Peptidic
        15.6.2. Non-peptidic
    15.7. Market Value Forecast, by End-user, 2017-2031
        15.7.1. Hospitals
        15.7.2. Academic & Research Institutes
        15.7.3. Others
    15.8. Market Attractiveness Analysis
        15.8.1. By Radioisotope
        15.8.2. By Application
        15.8.3. By Source
        15.8.4. By Approach
        15.8.5. By Radiotracer Type
        15.8.6. By End-user
16. Competition Landscape
    16.1. Market Player Competition Matrix (by tier and size of companies)
    16.2. Market Share Analysis, by Company (2022)
    16.3. Company Profiles
        16.3.1. Advanced Accelerator Applications (Novartis AG)
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Product Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. Aurobindo Pharma
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Product Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. Bayer AG
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Product Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. Blue Earth Diagnostics (Bracco)
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Product Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. Cardinal Health
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Product Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. Clarity Pharmaceuticals
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Product Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. GE Healthcare
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Product Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. Jubliant Radiopharma
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Product Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. Lantheus Medical Imaging
            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.9.2. Product Portfolio
            16.3.9.3. Financial Overview
            16.3.9.4. SWOT Analysis
            16.3.9.5. Strategic Overview
        16.3.10. Navidea Biopharmaceuticals, Inc.
            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.10.2. Product Portfolio
            16.3.10.3. Financial Overview
            16.3.10.4. SWOT Analysis
            16.3.10.5. Strategic Overview
        16.3.11. SOFIE
            16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.11.2. Product Portfolio
            16.3.11.3. Financial Overview
            16.3.11.4. SWOT Analysis
            16.3.11.5. Strategic Overview
        16.3.12. Telix Pharmaceuticals
            16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.12.2. Product Portfolio
            16.3.12.3. Financial Overview
            16.3.12.4. SWOT Analysis
            16.3.12.5. Strategic Overview

ページTOPに戻る



List of Tables/Graphs

List of Tables

Table 01: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031

Table 02: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 03: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017–2031

Table 04: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017–2031

Table 05: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017–2031

Table 06: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 07: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Region, 2017–2031

Table 08: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031

Table 09: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 10: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017–2031

Table 11: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017–2031

Table 12: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017–2031

Table 13: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 14: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 15: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031

Table 16: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 17: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017–2031

Table 18: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017–2031

Table 19: EU Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017–2031

Table 20: EU Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 21: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031

Table 22: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 23: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017–2031

Table 24: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017–2031

Table 25: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017–2031

Table 26: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

Transparency Market Research社の製薬分野での最新刊レポート

本レポートと同じKEY WORD(industry)の最新刊レポート


よくあるご質問


Transparency Market Research社はどのような調査会社ですか?


トレンスペアレンシーマーケットリサーチ(Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/22 10:26

155.52 円

163.34 円

198.56 円

ページTOPに戻る